Get started
ARS Pharmaceuticals, Inc.ARS Pharmaceuticals, Inc.ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SPRY chart


Full chart

SPRY upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.09 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.51 USD
Net income (FY)
‪−54.37 M‬ USD
Revenue (FY)
‪30.00 K‬ USD
Shares float
‪51.02 M‬
Beta (1Y)
2.94

Employees


Employees (FY)
26
Change (1Y)
+6 +30.00%
Revenue / Employee (1Y)
‪1.15 K‬ USD
Net income / Employee (1Y)
‪−2.09 M‬ USD

About ARS Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Richard E. Lowenthal
Headquarters
San Diego
Website
ars-pharma.com
Founded
2015
FIGI
BBG00FZQGXG3
ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

SPRY news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SPRY is 11.18 USD — it has decreased by −1.24% in the past 24 hours. Watch ARS Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ARS Pharmaceuticals, Inc. stocks are traded under the ticker SPRY.
SPRY stock has fallen by −11.69% compared to the previous week, the month change is a −17.85% fall, over the last year ARS Pharmaceuticals, Inc. has showed a 120.51% increase.
We've gathered analysts' opinions on ARS Pharmaceuticals, Inc. future price: according to them, SPRY price has a max estimate of 35.00 USD and a min estimate of 26.00 USD. Watch SPRY chart and read a more detailed ARS Pharmaceuticals, Inc. stock forecast: see what analysts think of ARS Pharmaceuticals, Inc. and suggest that you do with its stocks.
SPRY reached its all-time high on Mar 18, 2021 with the price of 63.41 USD, and its all-time low was 2.55 USD and was reached on Sep 20, 2023. View more price dynamics on SPRY chart.
See other stocks reaching their highest and lowest prices.
SPRY stock is 6.78% volatile and has beta coefficient of 2.94. Track ARS Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is ARS Pharmaceuticals, Inc. there?
Today ARS Pharmaceuticals, Inc. has the market capitalization of ‪1.09 B‬, it has decreased by −4.16% over the last week.
Yes, you can track ARS Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
ARS Pharmaceuticals, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
SPRY earnings for the last quarter are −0.20 USD per share, whereas the estimation was −0.14 USD resulting in a −40.35% surprise. The estimated earnings for the next quarter are −0.14 USD per share. See more details about ARS Pharmaceuticals, Inc. earnings.
ARS Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪2.07 M‬ USD, despite the estimated figure of ‪575.00 K‬ USD. In the next quarter, revenue is expected to reach ‪5.57 M‬ USD.
SPRY net income for the last quarter is ‪−19.13 M‬ USD, while the quarter before that showed ‪−12.52 M‬ USD of net income which accounts for −52.83% change. Track more ARS Pharmaceuticals, Inc. financial stats to get the full picture.
No, SPRY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 26.00 employees. See our rating of the largest employees — is ARS Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARS Pharmaceuticals, Inc. EBITDA is ‪−60.44 M‬ USD, and current EBITDA margin is ‪−224.82 K‬%. See more stats in ARS Pharmaceuticals, Inc. financial statements.
Like other stocks, SPRY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARS Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARS Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARS Pharmaceuticals, Inc. stock shows the neutral signal. See more of ARS Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.